BMS Counting On Initial Combo Use For Glucovance To Supplant Glucophage
Executive Summary
Bristol-Myers Squibb's Glucovance (metformin/glyburide) is emerging from FDA in time to give Bristol a half a year or more to transfer the market from its $1.9 bil. single-agent product Glucophage to the new combo.
You may also be interested in...
Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin
Bristol-Myers Squibb's metformin/glyburide combination product Glucovance has a 1.5% share of the diabetes market one month after launch, Bristol told securities analysts Sept. 28 in New York City.
Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin
Bristol-Myers Squibb's metformin/glyburide combination product Glucovance has a 1.5% share of the diabetes market one month after launch, Bristol told securities analysts Sept. 28 in New York City.
Bristol Glucovance
Average wholesale price listed by First DataBank for metformin/glyburide combo (500 mg/2.5 mg) is $78.32 for 100 tablets, 11.8% above Bristol's Glucophage (metformin) 500 mg. The product was approved July 31 (1"The Pink Sheet" Aug. 7, p. 5)